SPOTLIGHT -
Evaluating Treatment Options and the Multidisciplinary Care of Ocular Toxicities of MEK Inhibitors
David L. DeRemer, PharmD, BCOP, and Bently P. Doonan, MD, MS, share a perspective on ocular toxicities associated with MEK inhibition.